Literature DB >> 29932782

PARP1 inhibitor eliminated imatinib-refractory chronic myeloid leukemia cells in bone marrow microenvironment conditions.

Paulina Podszywalow-Bartnicka1,2, Silvia Maifrede1, Bac Viet Le1,2, Margaret Nieborowska-Skorska1, Katarzyna Piwocka2, Tomasz Skorski1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29932782      PMCID： PMC6309580          DOI： 10.1080/10428194.2018.1471602

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  14 in total

1.  Bone marrow mesenchymal stromal cells non-selectively protect chronic myeloid leukemia cells from imatinib-induced apoptosis via the CXCR4/CXCL12 axis.

Authors:  Fabrizio Vianello; Federica Villanova; Veronica Tisato; Stefania Lymperi; Ka-Kei Ho; Ana R Gomes; David Marin; Dominique Bonnet; Jane Apperley; Eric W-F Lam; Francesco Dazzi
Journal:  Haematologica       Date:  2010-02-23       Impact factor: 9.941

2.  Downregulation of BRCA1 protein in BCR-ABL1 leukemia cells depends on stress-triggered TIAR-mediated suppression of translation.

Authors:  Paulina Podszywalow-Bartnicka; Magdalena Wolczyk; Monika Kusio-Kobialka; Kamila Wolanin; Krzysztof Skowronek; Margaret Nieborowska-Skorska; Yashodhara Dasgupta; Tomasz Skorski; Katarzyna Piwocka
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

3.  BCR/ABL stimulates WRN to promote survival and genomic instability.

Authors:  Artur Slupianek; Tomasz Poplawski; Stanislaw K Jozwiakowski; Kimberly Cramer; Dariusz Pytel; Ewelina Stoczynska; Michal O Nowicki; Janusz Blasiak; Tomasz Skorski
Journal:  Cancer Res       Date:  2010-12-01       Impact factor: 12.701

4.  BCR-ABL down-regulates the DNA repair protein DNA-PKcs.

Authors:  E Deutsch; A Dugray; B AbdulKarim; E Marangoni; L Maggiorella; S Vaganay; R M'Kacher; S D Rasy; F Eschwege; W Vainchenker; A G Turhan; J Bourhis
Journal:  Blood       Date:  2001-04-01       Impact factor: 22.113

5.  Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors.

Authors:  Margaret Nieborowska-Skorska; Piotr K Kopinski; Regina Ray; Grazyna Hoser; Danielle Ngaba; Sylwia Flis; Kimberly Cramer; Mamatha M Reddy; Mateusz Koptyra; Tyrone Penserga; Eliza Glodkowska-Mrowka; Elisabeth Bolton; Tessa L Holyoake; Connie J Eaves; Sabine Cerny-Reiterer; Peter Valent; Andreas Hochhaus; Timothy P Hughes; Heiko van der Kuip; Martin Sattler; Wieslaw Wiktor-Jedrzejczak; Christine Richardson; Adrienne Dorrance; Tomasz Stoklosa; David A Williams; Tomasz Skorski
Journal:  Blood       Date:  2012-03-12       Impact factor: 22.113

6.  Down-regulation of BRCA1 in BCR-ABL-expressing hematopoietic cells.

Authors:  Eric Deutsch; Sylvie Jarrousse; Dorothee Buet; Aymeric Dugray; Marie-Laure Bonnet; Marie-Catherine Vozenin-Brotons; Francois Guilhot; Ali G Turhan; Jean Feunteun; Jean Bourhis
Journal:  Blood       Date:  2003-02-06       Impact factor: 22.113

7.  Functionally distinct human marrow stromal cell lines immortalized by transduction with the human papilloma virus E6/E7 genes.

Authors:  B A Roecklein; B Torok-Storb
Journal:  Blood       Date:  1995-02-15       Impact factor: 22.113

8.  BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance.

Authors:  Mateusz Koptyra; Rafal Falinski; Michal O Nowicki; Tomasz Stoklosa; Ireneusz Majsterek; Margaret Nieborowska-Skorska; Janusz Blasiak; Tomasz Skorski
Journal:  Blood       Date:  2006-03-09       Impact factor: 22.113

9.  Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition.

Authors:  King Pan Ng; Aditi Manjeri; Kian Leong Lee; Weijie Huang; Soo Yong Tan; Charles T H Chuah; Lorenz Poellinger; S Tiong Ong
Journal:  Blood       Date:  2014-04-04       Impact factor: 22.113

10.  Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells.

Authors:  Margaret Nieborowska-Skorska; Katherine Sullivan; Yashodhara Dasgupta; Paulina Podszywalow-Bartnicka; Grazyna Hoser; Silvia Maifrede; Esteban Martinez; Daniela Di Marcantonio; Elisabeth Bolton-Gillespie; Kimberly Cramer-Morales; Jaewong Lee; Min Li; Artur Slupianek; Daniel Gritsyuk; Sabine Cerny-Reiterer; Ilona Seferynska; Tomasz Stoklosa; Lars Bullinger; Huaqing Zhao; Vera Gorbunova; Katarzyna Piwocka; Peter Valent; Curt I Civin; Markus Muschen; John E Dick; Jean Cy Wang; Smita Bhatia; Ravi Bhatia; Kolja Eppert; Mark D Minden; Stephen M Sykes; Tomasz Skorski
Journal:  J Clin Invest       Date:  2017-05-08       Impact factor: 14.808
View more
  1 in total

Review 1.  PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword.

Authors:  Clifford M Csizmar; Antoine N Saliba; Elizabeth M Swisher; Scott H Kaufmann
Journal:  Cancers (Basel)       Date:  2021-12-20       Impact factor: 6.639
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.